Agilent Technologies, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Agilent Technologies, Inc. (NYSE: A) provides instruments, software, services, and consumables for the life sciences, diagnostics, chemical analysis, and applied markets. The company offers a broad portfolio of products and services including gas chromatography and liquid chromatography systems; mass spectrometry and molecular spectroscopy instruments; microarrays, automation, and informatics solutions; bioreagents, FISH probes, target enrichment, and next-generation sequencing tools; immunohistochemistry and pathology solutions; genomics, proteomics, and cell analysis platforms; sample preparation, GC and HPLC columns, spectrometry supplies, and consumables; as well as laboratory management services encompassing enterprise asset management, compliance support, training, and CrossLab virtual assist for remote technical support. Headquartered in Santa Clara, California, Agilent operates globally in more than 100 countries, serving analytical laboratories, pharmaceutical, biopharma, clinical diagnostics, environmental, forensics, food, energy, academia, and government sectors; it was spun off from Hewlett-Packard in 1999. Recent developments include the completion of its $925 million acquisition of BIOVECTRA, Inc., a Canada-based contract development and manufacturing organization specializing in biologics, active pharmaceutical ingredients, sterile fill-finish, plasmid DNA, mRNA, lipid nanoparticles, antibody-drug conjugates, and high-potency APIs, enhancing Agilent's CDMO capabilities for gene editing and therapeutics; a $7 million investment to modernize R&D and applications labs in Delaware; the launch of the Agilent Innovation Hub in partnership with the University of Melbourne; a strategic collaboration with SeqOne for liquid biopsy data analysis in oncology; and expansions such as a $725 million nucleic acid therapeutics facility in Frederick, Colorado, alongside new product launches driving growth in specialty CDMO services for siRNA and GLP-1 modalities.
Agilent Technologies, Inc. (A) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
Agilent (A) Reliance on International Sales: What Investors Need to Know
Agilent Q2 Earnings Call Shows Ignite Driving a Higher Outlook
Why Agilent Technologies Stock Triumphed on Thursday
Agilent, Unusual Machines, Best Buy And Other Big Stocks Moving Higher On Thursday
Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory
Agilent Technologies, Inc. (A) Q2 2026 Earnings Call Transcript
Agilent Technologies Q2 Earnings Call Highlights
Agilent (A) Reports Q2 Earnings: What Key Metrics Have to Say
Agilent Technologies (A) Tops Q2 Earnings and Revenue Estimates
Agilent raises 2026 profit forecast on strong demand for lab tools
Agilent Reports Second-Quarter Fiscal Year 2026 Financial Results
Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control
Agilent Launches New GC Systems with GC Assist to Improve Laboratory Efficiency and Data Quality
Agilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality Control
Agilent Launches New GC Systems with GC Assist to Improve Laboratory Efficiency and Data Quality
Agilent Unveils the 9500 ICP-MS: Redefining Trace Element Analysis
Seeking Clues to Agilent (A) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics